Recursion to Participate in Upcoming Investor Conference
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company, announced its participation in the SVB Securities Global Biopharma Conference scheduled for February 14-16, 2023. This event highlights Recursion's mission to advance drug discovery through its innovative platform that integrates biology, chemistry, and technology. The company utilizes cutting-edge machine learning algorithms and operates one of the world's most powerful supercomputers to analyze a vast dataset, enhancing drug development.
Headquartered in Salt Lake City, Recursion is also active in Toronto, Montreal, and the San Francisco Bay Area. For additional information, visit www.recursion.com.
- None.
- None.
SVB Securities Global Biopharma Conference —February 14 through February 16, 2023
About Recursion
Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Forward-Looking Statements
This press release contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the closing of the private placement, registration of the shares of Class A common stock being issued and sold in the private placement, Recursion's use of the proceeds from the private placement, Recursion's preclinical and clinical programs, and all other statements that are not statements of historical facts. Forward-looking statements may or may not include identifying words such as "intend," "may," "expect," "plan," and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; and other risks and uncertainties such as those described under the heading "Risk Factors" in our filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/recursion-to-participate-in-upcoming-investor-conference-301736079.html
SOURCE Recursion
FAQ
When is Recursion participating in the SVB Securities Global Biopharma Conference?
What is the significance of Recursion's participation in the upcoming investor conference?
Where is Recursion headquartered?
What technologies does Recursion utilize for drug discovery?
What is the stock symbol for Recursion?
